Hook: The First CME Lawsuit Since 2022
On a quiet August afternoon, the Chicago Mercantile Exchange filed a complaint against the CFTC and Kalshi. The target: Kalshi’s Bitcoin perpetual futures contract. The CME argued that the product is a “swap,” not a “futures contract with no fixed expiration.” The implications are seismic. If the court agrees, every CFTC-approved perpetual product—gold, silver, stock indices, copper—could be retroactively reclassified. The entire narrative of “regulated perpetuals” would collapse. I’ve been tracking this space since the BitMEX era, and I can tell you: this is not a technical dispute. It’s a turf war over the future of leveraged derivatives. Check the chain, ignore the noise. The truth is on-chain, not in the chat.
Context: The Death of Offshore Perpetuals and the Birth of a New Venue
Perpetual futures are not new. BitMEX invented them in 2016, and for a decade, they dominated offshore crypto trading. But in July 2026, BitMEX announced its closure, citing regulatory pressure and declining market share. Analysts called it “the end of the offshore perpetual era.” Enter Kalshi, a CFTC-regulated exchange that had been running prediction markets. In May 2026, the CFTC approved Kalshi’s Bitcoin perpetual contract—the first of its kind under U.S. commodity regulation. The product launched on June 3, 2026, and within two weeks, Kalshi’s CEO claimed a trading volume of $5.5 billion. That’s $5.5 billion in a market that CME, with its legacy futures, had largely ignored.
But Kalshi didn’t stop with Bitcoin. In August, the exchange filed applications to list perpetual futures on gold, silver, the S&P 500, the Nasdaq-100, the Dow Jones, and copper. The message was clear: Kalshi wants to become the standard for regulated perpetuals across all asset classes. The CME, which dominates fixed-expiry futures in equity indices and commodities, saw the threat. The lawsuit is a defensive move.
Core: The Mechanics of a Regulated Perpetual – Innovation or Packaging?
Let’s cut through the hype. From a technical standpoint, a perpetual future is a simple structure: no expiration date, a funding rate mechanism to anchor the price to the spot index, and leverage. The real innovation here is not the trading engine—it’s the regulatory wrapper. Kalshi has built a “parameterizable” perpetual system, likely using a multi-asset index oracle, a funding rate calculation engine, and a liquidation engine that handles extreme volatility. The CME’s lawsuit focuses on the legal definition: is a contract with no fixed expiration a “future” or a “swap”? Under the Commodity Exchange Act, the distinction matters for margin, clearing, and tax treatment.
Based on my experience analyzing derivative protocols—I spent 2022 studying Aave v2’s risk models—the real risk here is not the code but the legal classification. Kalshi’s product uses central clearing, standardized margin requirements, and CFTC oversight. That’s the same framework as a CME future. The CME’s argument that a perpetual is a “swap” is a stretch, but it’s not without merit. The funding rate, which is a periodic payment between long and short positions, resembles a swap’s floating leg. If the court sides with CME, Kalshi’s entire product suite could be reclassified as swaps, triggering different capital requirements and potentially forcing Kalshi to register as a swap execution facility.
Meanwhile, the market data is telling. Kalshi’s Bitcoin perpetual volume hit $5.5 billion in two weeks. For a retail-heavy product, that’s impressive. But compare it to CME’s average daily volume of $1.5 billion in Bitcoin futures—that’s $30 billion in two weeks. Kalshi is still a minnow. The stock index perpetuals, if approved, could attract more institutional interest, but they face a chicken-and-egg liquidity problem. The Cboe, for example, launched binary options on the S&P 500 through Interactive Brokers, but those are fixed-expiry, not perpetual. The incumbents are not standing still.
Contrarian: The Hidden Risk Is Not the Lawsuit—It’s the Distribution
Everyone is focused on the CME lawsuit. But the deeper risk is distribution. Kalshi’s Bitcoin perpetual thrived because crypto traders already knew the product. For stock index perpetuals, the target audience is different: retail investors who use Robinhood, Schwab, or Interactive Brokers. Those brokers have their own relationships with CME and Cboe. Kalshi does not yet have a distribution network. The Cboe’s binary options were distributed through Interactive Brokers—a clear signal that brokerage integration is the real moat.
Financial markets are not about the best product. They are about the deepest liquidity. CME’s S&P 500 futures have a daily volume of $100 billion. Kalshi’s stock index perpetual, even if approved, will start at zero. The first few months will determine whether it becomes a viable alternative or a niche product for speculation. The CFTC’s approval timeline is uncertain: the commission has not set a review schedule for the index applications. If the CME lawsuit drags on, the CFTC might delay approvals to avoid contradicting a potential court ruling.
Another blind spot: the funding rate mechanism. In crypto perpetuals, funding rates are based on the difference between the perpetual price and the spot index. For stock indices, the spot index is well-defined, but the arbitrageurs who keep the price aligned are typically quantitative hedge funds. Those funds are already trading CME futures and ETFs. They might not want to allocate capital to a new, illiquid market. Without strong arbitrage, the perpetual could trade at a persistent premium or discount, making it unattractive for hedgers.
Takeaway: The Next Narrative Is Not “Regulated Perpetuals” but “Regulatory War”
Forget the technical specs. The next six months will be defined by the legal battle between CME and Kalshi/CFTC. If the court upholds Kalshi’s classification, we will see a flood of regulated perpetuals across asset classes, forcing CME and Cboe to launch their own versions. If the court sides with CME, the entire concept of a regulated perpetual future could be banned in the U.S., pushing volume back to offshore venues or decentralized protocols.
My advice: watch the court docket, not the volume numbers. The true signal is the legal interpretation of “no fixed expiration.” The truth is on-chain, but the fate of this market is in the courtroom. Check the chain, ignore the noise. The next narrative is not about product innovation—it’s about the boundaries of financial regulation. And that’s a story that will unfold slowly, with each ruling resetting the market’s expectations.